Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three ...

Sparsentan is expected to be funded in England by 27 June 2025, within 90 days of the final guidance publication. IgA ...

(Reuters) - Australian biotech giant CSL Ltd is in exclusive talks to buy Vifor Pharma in a A$10 billion ($7.10 billion) deal, the Australian newspaper reported on Thursday, sending the Swiss ...

12 Underscoring the importance of the NICE recommendation for IgA nephropathy patients and their communities, Dr. Vinicius Gomes De Lima, Head of Global Medical Affairs at CSL Vifor said ...

CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its competitor’s products.

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney fai ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Decades into its tenure as a drug seller, CSL Behring has finally dipped its toe into the waters of TV advertising. | Decades ...

The sporting goods industry stepped onto the global health stage at a landmark side event at the World Health Assembly this week in Geneva, hosted by the World Federation of the Sporting Goods ...